Trial results reported Friday by the Lancet, the British medical journal responsible for publishing some of the earliest research on the coronavirus, found that Russia's Gameleya Institute-developed SARS-CoV-2 vaccine is both effective and safe, though scientists cautioned that long-term study is still required.

The vaccine, the researchers found, produced an antibody response in all test subjects while causing no serious adverse effects. The results mark the latest stamp of legitimacy for the vaccine developed by the world-reknowned Gameleya Institute, and show how the early and intense skepticism expressed by some in the West might have been premature.